Literature DB >> 3469171

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.

H S Hochster, M D Green, R H Blum, J C Wernz, J L Speyer, F M Muggia.   

Abstract

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3469171     DOI： 10.1007/BF00179596

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  8 in total

1.  Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs.

Authors:  A Di Marco; F Zunino; A M Casazza
Journal:  Antibiot Chemother (1971)       Date:  1978

2.  Antitumor activity of 4-demethoxydaunorubicin administered orally.

Authors:  A Di Marco; A M Casazza; G Pratesi
Journal:  Cancer Treat Rep       Date:  1977-08

3.  Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.

Authors:  R A Joss; J P Obrecht; P Alberto; P Siegenthaler; A VanHelvoirt; F Cavalli
Journal:  Cancer Treat Rep       Date:  1984-03

4.  Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.

Authors:  E Berman; R E Wittes; B Leyland-Jones; E S Casper; R J Gralla; J Howard; L Williams; R Baratz; C W Young
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

5.  4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

Authors:  A M Carella; G Santini; M Martinengo; D Giordano; S Nati; A Congiu; R Cerri; M Risso; E Damasio; E Rossi
Journal:  Cancer       Date:  1985-04-01       Impact factor: 6.860

6.  Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.

Authors:  A N Daghestani; Z A Arlin; B Leyland-Jones; T S Gee; S J Kempin; R Mertelsmann; D Budman; P Schulman; R Baratz; L Williams
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

7.  Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.

Authors:  S Kaplan; C Sessa; Y Willems; M A Pacciarini; V Tamassia; F Cavalli
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Antileukemic activity of 4-demethoxydaunorubicin in mice.

Authors:  A M Casazza; G Pratesi; F Giuliani; A Di Marco
Journal:  Tumori       Date:  1980-10-31
  8 in total
  3 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

3.  Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology.

Authors:  H Hochster; M Green; L Liebes; J L Speyer; J Wernz; R Blum; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.